SCHEMBL30656790

SCHEMBL30656790

COCCn1cnc2ccc(N)c(Br)c2c1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.44
MEN1 O00255 3/20 0.44
HSD17B10 Q99714 3/20 0.41
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
NPC1 O15118 1/20 0.41
GLA P06280 1/20 0.41
GAA P10253 1/20 0.41
BRAF P15056 1/20 0.40
MAPT P10636 4/20 0.38
PDE4A P27815 1/20 0.38
ADORA2A P29274 1/20 0.38
ADORA2B P29275 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38
LMNA P02545 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24166131 1.00 KMT2A (0.44) KMT2AMEN1HSD17B10KDM4EALDH1A1
SCHEMBL30656781 0.82 KMT2A (0.42) KMT2AMEN1HSD17B10KDM4EALDH1A1
SCHEMBL24166470 0.82 KMT2A (0.42) KMT2AMEN1HSD17B10KDM4EALDH1A1
SCHEMBL30656811 0.81 ALDH1A1 (0.43) KMT2AMEN1HSD17B10KDM4EALDH1A1
SCHEMBL24166503 0.81 ALDH1A1 (0.43) KMT2AMEN1HSD17B10KDM4EALDH1A1
SCHEMBL22831920 0.81 KMT2A (0.48) KMT2AMEN1HSD17B10KDM4EALDH1A1
SCHEMBL24166155 0.80 KMT2A (0.40) KMT2AMEN1HSD17B10KDM4EALDH1A1
SCHEMBL30656856 0.80 KMT2A (0.40) KMT2AMEN1HSD17B10KDM4EALDH1A1
SCHEMBL24879123 0.80 BRAF (0.46) KMT2AMEN1HSD17B10KDM4EALDH1A1
SCHEMBL24878868 0.80 BRAF (0.44) KMT2AMEN1HSD17B10KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528777-B2 Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2026-01-20 US disclosed
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2023-11-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF ATG7, GOT1, LIPC KMT2A 3393/4885MEN1 3700/4885HSD17B10 271/4885
US-12528777-B2 Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof ATG7, GOT1, ULK1 KMT2A 2468/4885MEN1 4365/4885HSD17B10 478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.